AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD
The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US
Read More
Tag: Ultomiris
CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris
European drug regulator has recommended Ultomiris for use in children and adolescents with PNH
Read More
SMC endorses Alexion’s Ultomiris
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read More
NICE recommends Alexion’s PNH treatment Ultomiris
C5 complement inhibitor approved to treat PNH in adult patients with haemolysis
Read More
SMC approves funding for four new medicines on the NHS
BMS’ MS therapy Zeposia and AbbVie’s JAK inhibitor Rinvoq among latest approvals
Read More
EU approval for Alexion’s PNH drug Ultomiris
The decision allows use of the drug in patients with haemolysis with clinical symptoms indicative of high disease activity
Read More
Ultomiris successful in Phase III study
Alexion Pharmaceuticals’ Ultomiris has been found to be successful in treating atypical haemolytic uremic syndrome (aHUS) in a Phase III study.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
